# BBWI - Bath & Body Works, Inc.

**Date:** 2026-02-02
**Status:** RESEARCH - PASS (with caveats)
**Tier:** C (Turnaround/Speculative)
**Quality Score:** 3/10
**Decision:** WATCHLIST - Wait for turnaround evidence before committing capital

---

## Executive Summary

Bath & Body Works trades at 6.9x trailing P/E and 17.8% FCF yield, deeply discounted vs specialty retail peers (~19x P/E). The cheapness is warranted by: (1) declining revenue and earnings, (2) massive debt load with negative equity, (3) failed growth strategy requiring a multi-quarter turnaround, (4) active securities fraud litigation, and (5) competitive pressures from digital-first brands. However, the business still generates ~$660M/year in FCF, covers interest 5x, and trades near bear-case DCF value. This is a classic value trap vs turnaround debate.

---

## Key Metrics

| Metric | Value | Comment |
|--------|-------|---------|
| Price | $22.32 (EUR 18.83) | Down 47% from 52w high |
| Market Cap | $4.6B | |
| Trailing P/E | 6.9x | vs industry ~19x |
| Forward P/E | 8.7x | Implies earnings decline |
| Dividend Yield | 3.7% | $0.80/share annual |
| FCF Yield | ~14.3% | $660M FCF / $4.6B mcap |
| EV/EBITDA | ~6.0x | |
| Total Debt | $4.96B | Includes lease obligations |
| Long-Term Debt | $3.88B | |
| Net Debt | $4.74B | Cash $0.67B - Debt significant |
| Stockholders Equity | **-$1.39B** | NEGATIVE equity |
| Gross Margin | 44.1% | |
| Operating Margin | 10.1% | Down from 25% in FY2022 |
| Interest Coverage | 5.1x | Adequate but declining |
| Shares Outstanding | 205M | |

---

## 1. Why Is It So Cheap?

Multiple compounding negatives explain the discount:

**a) Revenue in structural decline.** Revenue has fallen from $7.88B (FY2022) to $7.31B (FY2025), a 7% decline over 3 years. Q3 FY2026 showed -1% YoY. Q4 FY2026 guided for high single-digit decline. Management admitted 2026 won't deliver full-year growth.

**b) Earnings deteriorating faster than revenue.** Operating income fell from $2.01B (FY2022) to $1.27B (FY2025) -- a 37% decline. Operating margin compressed from 25.5% to 17.4% (reported) and current TTM is ~10.1%. Elevated promotions, tariffs, and operating costs are compressing margins.

**c) Failed growth strategy.** Management admitted their "adjacencies, collaborations and promotions" strategy did NOT grow the customer base. They are now retreating to core categories.

**d) Massive leverage with negative equity.** Total debt $4.96B against a $4.6B market cap. Stockholders' equity is -$1.39B. This is an LBO-style capital structure inherited from the L Brands days. D/E shows 0.00 in screeners because equity is negative (not because there's no debt).

**e) Securities fraud class action.** Filed after Q3 2025 results caused a 24.8% single-day stock drop. Alleges management misrepresented effectiveness of growth strategy. Adds uncertainty and potential financial liability.

**f) Competitive erosion.** Struggling to resonate with younger consumers. Digital-first competitors gaining share. Store traffic muted.

---

## 2. Revenue and Earnings Trajectory

| Fiscal Year (ends Jan) | Revenue | Operating Income | Net Income | EPS (est) |
|------------------------|---------|-----------------|------------|-----------|
| FY2022 (Jan 2022) | $7.88B | $2.01B | $1.33B | ~$5.50 |
| FY2023 (Jan 2023) | $7.56B | $1.38B | $0.80B | ~$3.30 |
| FY2024 (Jan 2024) | $7.43B | $1.28B | $0.88B | ~$3.80 |
| FY2025 (Jan 2025) | $7.31B | $1.27B | $0.80B | ~$3.50 |
| FY2026 (Jan 2026) est | ~$7.1B | ~$1.0B | ~$0.55B | ~$2.50-2.60 |

**Verdict: Declining.** Revenue, operating income, and margins are all trending down. The FY2022 peak was a COVID-driven anomaly (home goods boom). The business is normalizing to a lower steady state, and it's unclear where the floor is.

---

## 3. Balance Sheet - Actual Debt Situation

The D/E ratio shows 0.00 because **stockholders' equity is negative** (-$1.39B). This is NOT a debt-free company -- it is the opposite.

- **Total Debt:** $4.96B (including $1.08B current + $3.88B long-term)
- **Cash:** $0.67B
- **Net Debt:** ~$4.3B
- **Debt/EBITDA:** 3.06x (manageable but elevated)
- **Interest Coverage:** 5.1x (adequate)

**Positive:** Company has been deleveraging. Total debt down from $6.05B (FY2023) to $4.96B (FY2025). Cash flow covers interest comfortably.

**Negative:** Equity is deeply negative. At current earnings trajectory, it would take many years to restore positive equity. The capital structure is fragile -- any sustained earnings decline could pressure debt covenants.

---

## 4. FCF Generation and Sustainability

| FY | FCF | OCF | CapEx | Buybacks | Dividends |
|----|-----|-----|-------|----------|-----------|
| 2022 | $1,222M | $1,492M | -$270M | -$1,964M | -$120M |
| 2023 | $816M | $1,144M | -$328M | -$1,312M | -$186M |
| 2024 | $656M | $954M | -$298M | -$148M | -$182M |
| 2025 | $660M | $886M | -$226M | -$401M | -$177M |

FCF has declined from $1.2B to $660M but remains substantial. At $660M FCF, the stock yields ~14% on market cap. However:

- FCF is declining in line with earnings
- $250M cost savings program may stabilize FCF at $600-700M range
- Buybacks + dividends ($578M in FY2025) consume 88% of FCF, leaving little for debt reduction
- If earnings decline further, dividend ($177M/yr) could come under pressure

**Sustainability: MODERATE.** FCF remains strong but the trajectory is negative and capital allocation prioritizes shareholder returns over deleveraging, which is risky given the balance sheet.

---

## 5. Competitive Moat Assessment

**Moat: NARROW (deteriorating)**

**Strengths:**
- Strong brand recognition in home fragrance/body care category
- ~1,850 stores creates physical presence and impulse purchase opportunities
- Loyal customer base (though shrinking)
- High gross margins (44%) suggest some pricing power
- International licensing model is asset-light

**Weaknesses:**
- Products are NOT truly differentiated -- candles and soaps face low barriers to entry
- No meaningful switching costs
- Brand losing relevance with younger consumers
- Digital channel underdeveloped vs competitors
- Mall-heavy footprint is a structural disadvantage
- Promotional dependency erodes brand equity

**Verdict:** The moat exists but is narrow and eroding. This is a brand franchise business where the franchise value is declining. Not a "wide moat" in any Buffett sense.

---

## 6. Valuation

### DCF (via dcf_calculator.py with scenarios)

| Scenario | Fair Value/Share | MoS% at $22.32 |
|----------|-----------------|-----------------|
| Bear | $21.83 | -2.2% (NO margin) |
| Base | $33.43 | +49.8% |
| Bull | $49.86 | +123.4% |

**Note:** DCF assumes continued FCF generation. If FCF deteriorates further, bear case is the relevant scenario.

### P/E Multiples Approach

- Current EPS: ~$3.30 (TTM). Forward EPS: ~$2.50-2.60
- Specialty retail average P/E: ~19x (irrelevant for declining business)
- Distressed/declining retail P/E: 8-12x
- Conservative fair P/E for BBWI: 8-10x (given declining trajectory)

| Basis | P/E Applied | Fair Value |
|-------|------------|------------|
| TTM EPS $3.30 x 8x | Conservative | $26.40 |
| TTM EPS $3.30 x 10x | Moderate | $33.00 |
| Fwd EPS $2.55 x 8x | Conservative-Forward | $20.40 |
| Fwd EPS $2.55 x 10x | Moderate-Forward | $25.50 |

### EV/EBITDA Approach

- Current EBITDA: ~$1.6B. Applying 6-8x EV/EBITDA:
- EV range: $9.6B - $12.8B. Less net debt $4.3B = Equity $5.3B - $8.5B
- Per share: $25.85 - $41.46

### Synthesis

| Method | Bear | Base | Bull |
|--------|------|------|------|
| DCF | $21.83 | $33.43 | $49.86 |
| P/E (forward) | $20.40 | $25.50 | $33.00 |
| EV/EBITDA | $25.85 | $33.00 | $41.46 |
| **Weighted Avg** | **$22.50** | **$29.00** | **$38.00** |

**Fair value estimate: $27-30 range (base case), giving ~20-35% upside from $22.32.**

The margin of safety at current price is THIN on bear case ($22.50) but meaningful on base case ($29). This is the core tension.

---

## 7. Key Risks

1. **Structural decline (HIGH):** Revenue may not stabilize. If the category is ex-growth and the brand is fading, current earnings are the ceiling, not the floor.

2. **Leverage (HIGH):** $5B debt on a declining business. Any earnings miss could trigger covenant issues or rating downgrades. Refinancing risk when bonds mature.

3. **Turnaround execution (HIGH):** New CEO's plan won't show results until H2 FY2027. 3+ quarters of poor results ahead. Amazon partnership is unproven.

4. **Securities litigation (MEDIUM):** Class action could result in settlement costs ($50-200M). Adds management distraction.

5. **Consumer discretionary risk (MEDIUM):** Candles and soaps are discretionary. Recession would accelerate decline.

6. **Dividend sustainability (MEDIUM):** $177M/yr dividend is safe at current FCF but at risk if earnings decline further. A cut would be devastating for the stock.

7. **Tariff exposure (MEDIUM):** Some products sourced from China. Tariff escalation would compress margins further.

---

## Quality Score: 3/10

| Criterion | Score | Notes |
|-----------|-------|-------|
| ROE >15% consistent | 0 | Negative equity, metric meaningless |
| FCF positive 5+ years | 1 | Yes, but declining |
| Debt/Equity <1.0 | 0 | Negative equity, massively leveraged |
| Dividend 10+ years | 0 | Only since 2021 spin-off |
| Wide moat | 0 | Narrow and deteriorating |
| Revenue stability | 0 | Declining 3 consecutive years |
| Management quality | 0 | Failed strategy, new CEO unproven |
| Analyst coverage >10 | 1 | 13 analysts |
| Market cap >EUR 10B | 0 | EUR 3.9B |
| Defensive sector | 1 | Semi-discretionary (body care has some staple characteristics) |
| **Total** | **3/10** | **Tier C (35% MoS required)** |

---

## Tier Classification: C (Turnaround/Speculative)

With Quality Score 3/10, this requires **minimum 35% margin of safety** to buy.

- Base fair value: ~$29. At $22.32, MoS = 23%. **Does NOT meet 35% threshold.**
- To meet 35% MoS on base case ($29): need price at ~$18.85
- Bear fair value: ~$22.50. Current price offers essentially NO margin on bear case.

---

## Decision: WATCHLIST at $18.50 or below

**NOT a buy at $22.32.** The MoS is insufficient for a Tier C turnaround.

The thesis becomes interesting at **$18.50** (36% MoS on $29 base) or if:
- Two consecutive quarters of revenue stabilization/growth
- Evidence the Amazon partnership drives incremental sales
- Visible margin improvement from $250M cost savings
- Litigation resolved or reserved

**Catalysts to monitor:**
- Q4 FY2026 earnings: February 19, 2026 (17 days away)
- FY2027 guidance will be critical for turnaround visibility
- Amazon launch in 2026

---

## Autocritica

**Assumptions:** FCF stabilizes at ~$600-660M; turnaround takes 3+ quarters; no refinancing crisis.

**Biases detected:** Temptation to buy cheap P/E without sufficient weight on balance sheet risk and declining trajectory. The 6.9x P/E is a siren song for value investors.

**Evidence I might be wrong:** The business DOES generate significant FCF. If the turnaround works and revenue stabilizes, this could be a 2-3x from here. But "if turnaround works" is exactly what Tier C pricing demands.

**What a top fund manager would do:** Wait for Q4 results and FY2027 guidance. If guidance shows path to revenue stability, buy aggressively. If guidance disappoints again, this is a value trap heading to $15.

---

*Sources: yfinance, Bath & Body Works IR, stockanalysis.com, Simply Wall St, TIKR, Seeking Alpha*
*Analysis date: 2026-02-02*
